Eight weeks of pills clear hepatitis C as well as twelve
The RESOLVE trial, published in The Lancet on 30 September 2026 and led by Dr Rakesh Aggarwal, enrolled 880 adults with hepatitis C who had no cirrhosis and had never been treated, at five public hospitals in Lucknow, New Delhi and Varanasi 264.
The median age was 35. Half took sofosbuvir-velpatasvir for eight weeks (443 people) and half for the standard twelve (437). Among those who finished and came back for the test twelve weeks later, 410 of 415 on the short course cleared the virus, 98.8 percent, against 397 of 401 on the long one, 99.0 percent 264. Counting everyone who never returned, the figures were 93.5 and 91.8 percent. Nobody had a drug-related serious adverse event or stopped because of one 264.
